West Pharma (WST) Tops Q1 EPS by 45c, provides guidance
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $342.63 --0%
Revenue Growth %: +2.5%
Financial Fact:
Interest income: 200K
Today's EPS Names:
VIVO, PMCB, PLCE, More
Revenue Growth %: +2.5%
Financial Fact:
Interest income: 200K
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q1 EPS of $2.13, $0.45 better than the analyst estimate of $1.68. Revenue for the quarter came in at $844.9 million versus the consensus estimate of $780.65 million.
GUIDANCE:
West Pharma sees FY2026 EPS of $8.40-$8.75, versus the consensus of $8.01. West Pharma sees FY2026 revenue of $3.295-3.35 billion, versus the consensus of $3.249 billion.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Macquarie Upgrades Broadcom Limited (AVGO) to Outperform
- Brady Corp. (BRC) Tops Q4 EPS by 1c ; Offers Guidance
- Momo (MOMO) Tops Q2 EPS by 8c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
